These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 22920732)

  • 1. Monoclonal antibody therapeutics: history and future.
    Buss NA; Henderson SJ; McFarlane M; Shenton JM; de Haan L
    Curr Opin Pharmacol; 2012 Oct; 12(5):615-22. PubMed ID: 22920732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic monoclonal antibodies: a little history, a lot of engineering, and... some clinical successes].
    Siberil S; Dutertre CA; Boix C; Teillaud JL
    Transfus Clin Biol; 2005 Jun; 12(2):114-22. PubMed ID: 15907389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tailor-made antibody therapeutics.
    Chowdhury PS; Wu H
    Methods; 2005 May; 36(1):11-24. PubMed ID: 15848071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody Engineering & Therapeutics 2015: The Antibody Society's annual meeting December 7-10, 2015, San Diego, CA.
    Parren PW; Burton DR; Bradbury A; Huston JS; Carter PJ; Veldman T; Chester KA; Larrick JW; Alfenito MR; Scott JK; Weiner LM; Adams GP; Reichert JM
    MAbs; 2015; 7(6):981-8. PubMed ID: 26421752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies.
    Majidi J; Barar J; Baradaran B; Abdolalizadeh J; Omidi Y
    Hum Antibodies; 2009; 18(3):81-100. PubMed ID: 19729803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The coming of age of engineered multivalent antibodies.
    Nuñez-Prado N; Compte M; Harwood S; Álvarez-Méndez A; Lykkemark S; Sanz L; Álvarez-Vallina L
    Drug Discov Today; 2015 May; 20(5):588-94. PubMed ID: 25757598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-bacterial monoclonal antibodies: back to the future?
    Oleksiewicz MB; Nagy G; Nagy E
    Arch Biochem Biophys; 2012 Oct; 526(2):124-31. PubMed ID: 22705202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations for the development of therapeutic monoclonal antibodies.
    Swann PG; Tolnay M; Muthukkumar S; Shapiro MA; Rellahan BL; Clouse KA
    Curr Opin Immunol; 2008 Aug; 20(4):493-9. PubMed ID: 18586093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineered antibodies take center stage.
    Huston JS; George AJ
    Hum Antibodies; 2001; 10(3-4):127-42. PubMed ID: 11847424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies in oncology therapeutics: present and future indications.
    Bhutani D; Vaishampayan UN
    Expert Opin Biol Ther; 2013 Feb; 13(2):269-82. PubMed ID: 23286740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of humanized antibodies as cancer therapeutics.
    Qu Z; Griffiths GL; Wegener WA; Chang CH; Govindan SV; Horak ID; Hansen HJ; Goldenberg DM
    Methods; 2005 May; 36(1):84-95. PubMed ID: 15848077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Historical development of monoclonal antibody therapeutics.
    Nissim A; Chernajovsky Y
    Handb Exp Pharmacol; 2008; (181):3-18. PubMed ID: 18071939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fc receptors: role in biology and antibody therapy.
    van de Winkel JG
    Immunol Lett; 2010 Jan; 128(1):4-5. PubMed ID: 19808048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection, design, and engineering of therapeutic antibodies.
    Presta LG
    J Allergy Clin Immunol; 2005 Oct; 116(4):731-6; quiz 737. PubMed ID: 16210043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody production: polyclonal-derived biotherapeutics.
    Newcombe C; Newcombe AR
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Mar; 848(1):2-7. PubMed ID: 16893686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humanized antibodies as potential drugs for therapeutic use.
    Merluzzi S; Figini M; Colombatti A; Canevari S; Pucillo C
    Adv Clin Path; 2000 Apr; 4(2):77-85. PubMed ID: 11080787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three decades of human monoclonal antibodies: past, present and future developments.
    Steinitz M
    Hum Antibodies; 2009; 18(1-2):1-10. PubMed ID: 19478393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal and recombinant antibodies, 30 years after ..
    Laffly E; Sodoyer R
    Hum Antibodies; 2005; 14(1-2):33-55. PubMed ID: 16424599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies as targeting and therapeutic agents: prospects for liver transplantation, hepatitis and hepatocellular carcinoma.
    Luk JM; Wong KF
    Clin Exp Pharmacol Physiol; 2006; 33(5-6):482-8. PubMed ID: 16700883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of protein therapeutics.
    De Groot AS; Scott DW
    Trends Immunol; 2007 Nov; 28(11):482-90. PubMed ID: 17964218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.